<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03384277</url>
  </required_header>
  <id_info>
    <org_study_id>IHBDH-IIT2017006</org_study_id>
    <nct_id>NCT03384277</nct_id>
  </id_info>
  <brief_title>Trial of Acquired Haemophilia With Steroid Combined With Cyclophosphamide Versus Steroid Combined With Rituximab</brief_title>
  <official_title>A Prospective, Randomized, Multicenter Clinical Trial of Acquired Haemophilia A With Steroid Combined With Cyclophosphamide Versus Steroid Combined With Rituximab</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhang Lei</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Qilu Hospital of Shandong University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tianjin First Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Second Affiliated Hospital of Kunming Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Henan Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institute of Hematology &amp; Blood Diseases Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Purpose:

      To evaluate the efficacy when administering steroid combined with small dose rituximab to
      eliminate the antibody in acquired hemophilia A patients compared to treatment using steroid
      with cyclophosphamide.

      The study will test the hypothesis that steroid combined with small dose rituximab is as
      effective as steroid combined with cyclophosphamide for FVIII inhibitor eradication in
      Chinese patients with acquired hemophilia A.

      Study design Allocation: Randomized Intervention Model: Parallel Assignment Masking: None
      (Open Label) Primary Purpose: Treatment
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective randomized multi-center controlled pilot trial comparing the regimen of
      steroid with rituximab and steroid with cyclophosphamide to eradicate anti-factor VIII
      antibodies in Chinese patients with acquired hemophilia A.

      Patients will be randomized to two regimens: methylprednisolone 0.8mg/kg/day (or equivalent
      corticosteroid doses) for 3 weeks (then tapering gradually,8 weeks in total) with rituximab
      (375mg/m2 for one dose) or methylprednisolone 0.8mg/kg/day (or equivalent corticosteroid
      doses) for 3 weeks (then tapering gradually,8 weeks in total) with cyclophosphamide
      2mg/kg/day until inhibitor negative(no longer than five weeks).

      Patients will be randomized to the treatment cohorts according to the biostatistical methods.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 26, 2017</start_date>
  <completion_date type="Anticipated">December 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of inhibitor eradication and time to attain first remission</measure>
    <time_frame>During 18 months</time_frame>
    <description>The proportion of patients achieving complete remission (CR) defined as titer FVIII inhibitor lower than 0.6 Bethesda unit, factor VIII level&gt; 50% and no bleeding events without bypass treatments for 24 hours and the time to attain first remission will be evaluated.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Relapse rate and time to relapse</measure>
    <time_frame>During 18 month</time_frame>
    <description>The proportion of patients who relapse and the time to relapse of each regimen will be measured.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Major bleeding and infection of two regimens</measure>
    <time_frame>During 18 months</time_frame>
    <description>The safety outcomes will be the occurrence of major bleeding and infection related immunosuppressive treatment adverse events.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Acquired Hemophilia A</condition>
  <arm_group>
    <arm_group_label>Steroid+Rituximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Methylprednisolone 0.8 mg/kg/day (or equivalent corticosteroid doses) for 3 weeks（then tapering gradually, 8 weeks in total）+Rituximab 375mg/m2 for one dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Steroid +Cyclophosphamide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Methylprednisolone 0.8 mg/kg/day (or equivalent corticosteroid doses) for 3 weeks （ then tapering gradually, 8 weeks in total）+ Cyclophosphamide 2 mg/kg/day until inhibitor negative (no longer than five weeks)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Steroid</intervention_name>
    <description>Methylprednisolone 0.8 mg/kg/day (or equivalent corticosteroid doses) for 3 weeks（then tapering gradually, 8 weeks in total）</description>
    <arm_group_label>Steroid+Rituximab</arm_group_label>
    <arm_group_label>Steroid +Cyclophosphamide</arm_group_label>
    <other_name>Corticosteroid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>375mg/m2 for one dose</description>
    <arm_group_label>Steroid+Rituximab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>cyclophosphamide 2 mg/kg/day until inhibitor negative (no longer than five weeks)</description>
    <arm_group_label>Steroid +Cyclophosphamide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18-70 years old

          -  Men or women

          -  Women post-menopausal or with ongoing contraception

          -  Diagnosis of acquired hemophilia A

          -  Patient must be insured

          -  Patient has provided written informed consent prior to enrollment

          -  Patient compliant

        Exclusion Criteria:

          -  Congenital hemophilia

          -  Ongoing treatment with prednisone &gt; 20mg/d （or equivalent corticosteroid doses） more
             than 1 month

          -  Ongoing treatment with prednisone &gt;0.7mg/kg（or equivalent corticosteroid doses） more
             than 10 days

          -  Pregnant and breastfeeding women

          -  Allergy to steroid

          -  Immunosuppressive agents treatment within 30 days

          -  Serum transaminase and bilirubin greater than 1.5 times the upper limit of normal
             value

          -  Hepatitis B surface antigen or hepatitis C antibody or HIV antibody (I + II) or
             syphilis antibody positive

          -  Patients with diabetes, hypertension, glaucoma, peptic ulcer, herpes zoster, pulmonary
             infection and so on, who should not be treated with glucocorticoids

          -  Patients with poor compliance

          -  Those who can not take contraceptive measures during the test period

          -  Patient who is considered by the investigator not suitable for clinical study

          -  Thrombocytopenia

          -  Leucocytopenia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lei Zhang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Blood disease hospital, Chinese academy of medical sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wei Liu, MD</last_name>
    <phone>+8613820261971</phone>
    <email>liuwei1@ihcams.ac.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lei Zhang, MD</last_name>
    <phone>+8613502118379</phone>
    <email>zhanglei1@ihcams.ac.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ethics Committee of Blood disease hospital, Chinese Academy of Medical Sciences</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300020</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lijun Liu, Master</last_name>
      <phone>+8613920927593</phone>
      <email>liulijun@ihcams.ac.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Collins P, Baudo F, Huth-Kühne A, Ingerslev J, Kessler CM, Castellano ME, Shima M, St-Louis J, Lévesque H. Consensus recommendations for the diagnosis and treatment of acquired hemophilia A. BMC Res Notes. 2010 Jun 7;3:161. doi: 10.1186/1756-0500-3-161.</citation>
    <PMID>20529258</PMID>
  </reference>
  <reference>
    <citation>Collins PW, Hirsch S, Baglin TP, Dolan G, Hanley J, Makris M, Keeling DM, Liesner R, Brown SA, Hay CR; UK Haemophilia Centre Doctors' Organisation. Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors' Organisation. Blood. 2007 Mar 1;109(5):1870-7. Epub 2006 Oct 17.</citation>
    <PMID>17047148</PMID>
  </reference>
  <reference>
    <citation>Lottenberg R, Kentro TB, Kitchens CS. Acquired hemophilia. A natural history study of 16 patients with factor VIII inhibitors receiving little or no therapy. Arch Intern Med. 1987 Jun;147(6):1077-81.</citation>
    <PMID>3109341</PMID>
  </reference>
  <reference>
    <citation>Collins P, Baudo F, Knoebl P, Lévesque H, Nemes L, Pellegrini F, Marco P, Tengborn L, Huth-Kühne A; EACH2 registry collaborators. Immunosuppression for acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2). Blood. 2012 Jul 5;120(1):47-55. doi: 10.1182/blood-2012-02-409185. Epub 2012 Apr 18.</citation>
    <PMID>22517903</PMID>
  </reference>
  <reference>
    <citation>Stasi R, Brunetti M, Stipa E, Amadori S. Selective B-cell depletion with rituximab for the treatment of patients with acquired hemophilia. Blood. 2004 Jun 15;103(12):4424-8. Epub 2004 Mar 2.</citation>
    <PMID>14996701</PMID>
  </reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 28, 2017</study_first_submitted>
  <study_first_submitted_qc>December 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 27, 2017</study_first_posted>
  <last_update_submitted>February 24, 2018</last_update_submitted>
  <last_update_submitted_qc>February 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Institute of Hematology &amp; Blood Diseases Hospital</investigator_affiliation>
    <investigator_full_name>Zhang Lei</investigator_full_name>
    <investigator_title>vice Director of Thrombosis and Hemostasis Center</investigator_title>
  </responsible_party>
  <keyword>Acquired hemophilia A</keyword>
  <keyword>Cyclophosphamide</keyword>
  <keyword>Rituximab</keyword>
  <keyword>Steroid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified individual participant data for all primary and secondary outcome will be made available</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

